Lipman Zoe M, Paramasivam Vijayakumar, Yosipovitch Gil, Germain Michael J
Dr Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA.
Division of Nephrology, Renal Transplant Associates of New England, Baystate Medical Center U Mass Medical School, Springfield, MA, USA.
Clin Kidney J. 2021 Oct 14;14(Suppl 3):i16-i22. doi: 10.1093/ckj/sfab167. eCollection 2021 Dec.
Chronic kidney disease (CKD)-associated pruritus (CKD-aP) is an underdiagnosed yet severely distressing condition that impacts 60% of patients on dialysis and many nondialysis patients with Stages 3-5 CKD. However, despite its high prevalence, there are currently limited treatment options available for these patients and a lack of treatment guidelines for clinicians. In this manuscript, we reviewed the available literature in order to evaluate the current management and treatment options for CKD-aP, including dialysis management, topical treatments, gabapentinoids, opioids and alternative medicine. We also review the available data on CKD-aP treatments in development and propose new guidelines for managing patients with CKD-aP.
慢性肾脏病(CKD)相关瘙痒(CKD-aP)是一种诊断不足但严重困扰患者的病症,影响60%的透析患者以及许多3-5期CKD非透析患者。然而,尽管其患病率很高,但目前这些患者可用的治疗选择有限,且缺乏针对临床医生的治疗指南。在本手稿中,我们回顾了现有文献,以评估CKD-aP的当前管理和治疗选择,包括透析管理、局部治疗、加巴喷丁类药物、阿片类药物和替代医学。我们还回顾了正在研发的CKD-aP治疗的现有数据,并提出了管理CKD-aP患者的新指南。